Drug Profile
IRL 1009
Alternative Names: IRL-1009Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Integrative Research Laboratories
- Class Neuroprotectants
- Mechanism of Action Central nervous system stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cognition disorders; Movement disorders
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Cognition-disorders in Sweden
- 28 Feb 2023 No recent reports of development identified for preclinical development in Movement-disorders in Sweden
- 23 Feb 2021 Preclinical development is ongoing in Sweden (Integrative Research Laboratories, February 2021)